ACHV News and Press, Achieve Life Sciences Inc. From 08/08/19

Achieve Life Sciences (NASDAQ: ACHV ): Q2 GAAP EPS of -$0.50 beats by $0.06 . More news on: Achieve Life Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SEATTLE and VANCOUVER, British Columbia , Aug. 8, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on t...

Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019 Canada NewsWire SEATTLE and VANCOUVER, British Columbia, July 30, 2019 SEATTLE and VANCOUVER, British Columbia , July 30, 2019 /CNW/ -- Ac...

Achieve Life Sciences ( ACHV +0.5% ) has extended its collaboration with the National Institutes of Health's (NIH) National Center for Complementary and Integrative Health (NCCIH) under which the latter will fund and provide research to support additional nonclinical studies as requ...

SEATTLE and VANCOUVER, British Columbia , July 23, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced it has extended its strategic collaboration with the National Center for Comple...

ContraVir Pharmaceuticals (NASDAQ: CTRV ) +42%  on FDA reaction to CRV431 plans. More news on: ContraVir Pharmaceuticals, Inc., Axovant Gene Therapies Ltd., Seadrill Limited, Stocks on the move, Read more ...

Achieve Life Sciences (NASDAQ: ACHV ) announces that an abstract featuring data from the Phase 2b ORCA-1 dose-selection study of cytisinicline for smoking cessation has been accepted for oral presentation at the Society for Research on Nicotine & Tobacco Europe (SRNT-E) Annua...

SEATTLE, Wash. and VANCOUVER, British Columbia , June 21, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced that an abstract featuring data from the Phase 2b ORCA-1 trial has bee...

Gainers:  Jaguar Health (NASDAQ: JAGX ) +60% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +40% . TORM (NASDAQ: TRMD ) +20% . Rekor Systems, Inc. (REKR) +17% . Enzo Biochem, Inc. (NYSE: ENZ ) +17% . Oxbridge Re Holdings (NASDAQ: OXBR ) +16% . Tenax Therapeutics (NASDAQ: TENX ) +1...

CymaBay Therapeutics (NASDAQ: CBAY )  -45%  on disappointing data on NASH candidate seladelpar. More news on: CymaBay Therapeutics, Inc., Achieve Life Sciences, Inc., Beyond Meat, Inc., Stocks on the move, Read more ...